Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

被引：22
|
作者：
Park, Jae H. [1 ]
Chung, Stephen S. [1 ]
Durham, Benjamin [2 ]
Chung, Young Rock [3 ]
Scott, Sasinya [2 ]
Getta, Bartlomiej [2 ]
Kim, Eunhee [2 ]
Saven, Alan [4 ]
Stone, Richard M. [5 ]
Rai, Kanti R. [6 ]
Grever, Michael R. [7 ]
Altman, Jessica K. [8 ]
Rosen, Neal [9 ]
Levine, Ross L. [2 ]
Berger, Michael [10 ]
Tallman, Martin S. [1 ]
Abdel-Wahab, Omar [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA
[4] Scripps Hlth, La Jolla, CA USA
[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[6] North Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA
[7] Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
[8] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[9] Mem Sloan Kettering Canc Ctr, Pharmacol, New York, NY 10021 USA
[10] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.682.682
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma
    Touat, Mehdi
    Gratieux, Julie
    Auliac, Stephanie Condette
    Sejean, Karine
    Aldea, Sorin
    Savatovsky, Julien
    Perkins, Geraldine
    Blons, Helene
    Ligon, Keith L.
    Idbaih, Ahmed
    Hollebecque, Antoine
    Gimenez-Roqueplo, Anne-Paule
    Laurent-Puig, Pierre
    Sanson, Marc
    Villa, Chiara
    Di Stefano, Anna Luisa
    NEUROLOGY, 2018, 91 (11) : 523 - 525
  • [2] VemurafenibPhotosensitivity, fatigue and development of drug resistance in BRAF-mutant hairy cell leukemia: 3 case reports
    Reactions Weekly, 2016, 1589 (1) : 194 - 194
  • [3] Novel mechanisms of resistance in BRAF-mutant melanoma
    Poulikakos, Poulikos I.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [4] Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia
    Park, Jae H.
    Chung, Stephen S.
    Chung, Young Rock
    Won, Helen
    Teruya-Feldstein, Julie
    Berger, Michael
    Khawaja, Talal T.
    Lacouture, Mario E.
    Levine, Ross L.
    Abdel-Wahab, Omar
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
  • [5] Vemurafenib: the first drug approved for BRAF-mutant cancer
    Bollag, Gideon
    Tsai, James
    Zhang, Jiazhong
    Zhang, Chao
    Ibrahim, Prabha
    Nolop, Keith
    Hirth, Peter
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) : 873 - 886
  • [6] Vemurafenib: the first drug approved for BRAF-mutant cancer
    Gideon Bollag
    James Tsai
    Jiazhong Zhang
    Chao Zhang
    Prabha Ibrahim
    Keith Nolop
    Peter Hirth
    Nature Reviews Drug Discovery, 2012, 11 : 873 - 886
  • [7] Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia
    Park, Jae H.
    Chung, Stephen S.
    Chung, Young Rock
    Won, Helen
    Kim, Eunhee
    Saven, Alan
    Wadleigh, Martha
    Stone, Richard M.
    Barrientos, Jacqueline C.
    Rai, Kanti R.
    Grever, Michael R.
    Altman, Jessica K.
    Lacouture, Mario E.
    Rosen, Neal
    Berger, Michael
    Levine, Ross L.
    Abdel-Wahab, Omar
    Tallman, Martin S.
    BLOOD, 2014, 124 (21)
  • [8] BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
    Dietrich, Sascha
    Pircher, Andreas
    Endris, Volker
    Peyrade, Frederic
    Wendtner, Clemens-Martin
    Follows, George A.
    Huellein, Jennifer
    Jethwa, Alexander
    Ellert, Elena
    Walther, Tatjana
    Liu, Xiyang
    Dyer, Martin J. S.
    Elter, Thomas
    Brummer, Tilman
    Zeiser, Robert
    Hermann, Michael
    Herold, Michael
    Weichert, Wilko
    Dearden, Claire
    Haferlach, Torsten
    Seiffert, Martina
    Hallek, Michael
    von Kalle, Christof
    Ho, Anthony D.
    Gaehler, Anita
    Andrulis, Mindaugas
    Steurer, Michael
    Zenz, Thorsten
    BLOOD, 2016, 127 (23) : 2847 - 2855
  • [9] VemurafenibResistance to vemurafenib in BRAF-mutant metastatic melanoma: case report
    Reactions Weekly, 2015, 1533 (1) : 437 - 437
  • [10] Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
    Wang, Weibin
    Kang, Helen
    Zhao, Yinu
    Min, Irene
    Wyrwas, Brian z
    Moore, Maureen
    Teng, Lisong
    Zarnegar, Rasa
    Jiang, Xuejun
    Fahey, Thomas J., III
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (02): : 634 - 643
12345